NEUROGENE INC (NGNE) Fundamental Analysis & Valuation

NASDAQ:NGNE • US64135M1053

Current stock price

19.52 USD
+0.22 (+1.14%)
Last:

This NGNE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NGNE Profitability Analysis

1.1 Basic Checks

  • In the past year NGNE has reported negative net income.
  • In the past year NGNE has reported a negative cash flow from operations.
  • In the past 5 years NGNE always reported negative net income.
  • NGNE had a negative operating cash flow in each of the past 5 years.
NGNE Yearly Net Income VS EBIT VS OCF VS FCFNGNE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a decent Return On Assets value of -31.31%, NGNE is doing good in the industry, outperforming 64.41% of the companies in the same industry.
  • NGNE's Return On Equity of -34.11% is fine compared to the rest of the industry. NGNE outperforms 72.15% of its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -34.11%
ROIC N/A
ROA(3y)-23.34%
ROA(5y)-31.36%
ROE(3y)-25.95%
ROE(5y)-36.27%
ROIC(3y)N/A
ROIC(5y)N/A
NGNE Yearly ROA, ROE, ROICNGNE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • NGNE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGNE Yearly Profit, Operating, Gross MarginsNGNE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NGNE Health Analysis

2.1 Basic Checks

  • NGNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NGNE has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, NGNE has more shares outstanding
  • Compared to 1 year ago, NGNE has an improved debt to assets ratio.
NGNE Yearly Shares OutstandingNGNE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
NGNE Yearly Total Debt VS Total AssetsNGNE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 5.73 indicates that NGNE is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.73, NGNE is doing good in the industry, outperforming 75.44% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that NGNE is not too dependend on debt financing.
  • NGNE has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.73
ROIC/WACCN/A
WACC9.38%
NGNE Yearly LT Debt VS Equity VS FCFNGNE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 16.56 indicates that NGNE has no problem at all paying its short term obligations.
  • NGNE has a Current ratio of 16.56. This is amongst the best in the industry. NGNE outperforms 94.20% of its industry peers.
  • NGNE has a Quick Ratio of 16.56. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 16.56, NGNE belongs to the best of the industry, outperforming 94.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.56
Quick Ratio 16.56
NGNE Yearly Current Assets VS Current LiabilitesNGNE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NGNE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 1.01% over the past year.
  • The Revenue for NGNE has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)1.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.01%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NGNE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.52% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.28%
EPS Next 2Y-19.31%
EPS Next 3YN/A
EPS Next 5Y42.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGNE Yearly Revenue VS EstimatesNGNE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
NGNE Yearly EPS VS EstimatesNGNE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2029 2030 2031 2032 2033 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. NGNE Valuation Analysis

4.1 Price/Earnings Ratio

  • NGNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGNE Price Earnings VS Forward Price EarningsNGNE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGNE Per share dataNGNE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

  • A cheap valuation may be justified as NGNE's earnings are expected to decrease with -19.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NGNE Dividend Analysis

5.1 Amount

  • NGNE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NGNE Fundamentals: All Metrics, Ratios and Statistics

NEUROGENE INC

NASDAQ:NGNE (3/31/2026, 11:32:32 AM)

19.52

+0.22 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)05-07
Inst Owners109.5%
Inst Owner Change7.51%
Ins Owners8.95%
Ins Owner Change3.58%
Market Cap302.36M
Revenue(TTM)N/A
Net Income(TTM)-90.35M
Analysts85.71
Price Target82.62 (323.26%)
Short Float %27.54%
Short Ratio23.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)37.29%
PT rev (3m)37.29%
EPS NQ rev (1m)-4.76%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)-3.4%
EPS NY rev (3m)-3.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.14
EV/EBITDA N/A
EPS(TTM)-4.24
EYN/A
EPS(NY)-5.49
Fwd EYN/A
FCF(TTM)-5.06
FCFYN/A
OCF(TTM)-4.98
OCFYN/A
SpS0
BVpS17.1
TBVpS17.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.31%
ROE -34.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.34%
ROA(5y)-31.36%
ROE(3y)-25.95%
ROE(5y)-36.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.56
Quick Ratio 16.56
Altman-Z 5.73
F-Score2
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)24.67%
Cap/Depr(5y)78.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.01%
EPS Next Y-26.28%
EPS Next 2Y-19.31%
EPS Next 3YN/A
EPS Next 5Y42.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.31%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROGENE INC / NGNE Fundamental Analysis FAQ

What is the fundamental rating for NGNE stock?

ChartMill assigns a fundamental rating of 2 / 10 to NGNE.


What is the valuation status of NEUROGENE INC (NGNE) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROGENE INC (NGNE). This can be considered as Overvalued.


Can you provide the profitability details for NEUROGENE INC?

NEUROGENE INC (NGNE) has a profitability rating of 1 / 10.


Can you provide the financial health for NGNE stock?

The financial health rating of NEUROGENE INC (NGNE) is 6 / 10.